drugset / Trial / NCT03620435
Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer
Phase 2
Unknown
25 enrolled
McGill University Health Centre/Research Institute of the McGill University Health Centre
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm phase II trial to (1) evaluate safety and toxicity profile of intravenous Atezolizumab (anti-PDL-1) administered in combination with TMT in patients with MIBC, (2) To determine the loco-regional control rate (LCR) of TMT combined with PDL-1 blockade.
Timeline
- Start
- 2018-05-01
- Primary completion
- 2020-05-30
- Completion
- 2020-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 840 mg | Intravenous |
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
Indications
No indication recorded.